Rosacea
Therapeutic area
Dermatology
Rare disease
No
- Definition
- A chronic erythematous skin disorder that affects the face. It is characterized by the development of redness in the cheeks, nose, and/or forehead and telangiectasia. Sometimes, the erythematous changes may involve the eyelids.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Rosacea
- Therapeutic area
- Dermatology
- rosacea
- acne rosacea
- Rosacea, Erythematotelangiectatic
- Rosacea, Papulopustular
- All therapeutic areas
- Dermatology
Sources for recorded values
- Severity
- Mild
- MONDO ID
- MONDO:0006604
- Parent condition
- MONDO:0005093
Related records
Broader conditions (5)
- Disease
- Disease by body system or component
- Human disease
- Integumentary system disorder
- Skin disorder
Narrower conditions (1)
- Rhinophyma
Trials (224)
- 4 Week In-Use Study Evaluating How Well-Tolerated a Skin Care Product Is on Adults With Facial Redness
- A 21 Day Pharmacokinetics Study in Papulopustular Rosacea
- A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"
- A Clinical Study Evaluating the Safety and Efficacy of IDP-115 in Patients With Rosacea
- A Clinical Trial to Determine the Effects of 40 Mg Doxycycline Versus a Placebo Control for the Treatment of Rosacea
- A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules
- A Double-Blinded, Randomized Placebo Controlled Pilot Study Comparing the Efficacy and Safety of IncobotulinumtoxinA Versus Saline Injections to the Cheek Region in Patients With Rosacea
- A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea
- A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
- A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily
- A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)
- A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.
- A Pilot Study on the Use of Seysara for Rosacea
- A Pilot Study Testing the Effects of Chemical Peels in Patients With Rosacea
- A Pilot Study to Explore the Role of Gut Flora in Acne
- A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
- A Safety and Efficacy Study of DRM02 in Subjects With Rosacea
- A Safety and Efficacy Study to Evaluate Rosacea
- A Study Comparing Ivermectin Cream 1%, Soolantra™ Cream 1%, PrROSIVER® Cream1% to Placebo Control in the Treatment of Moderate to Severe Facial Rosacea.
- A Study of a Polymeric Surfactant Technology Cleanser in Sensitive Skin Participants
Approved drugs (11)
- Azelaic acid
- Brimonidine tartrate
- Clobetasol
- Clocortolone acetate
- Diflorasone diacetate
- Doxycycline
- Ivermectin
- Metronidazole
- Metronidazole hydrochloride
- Minocycline hydrochloride
- Oxymetazoline hydrochloride
Drugs in development (35)
- Aminocaproic acid Early phase 1
- Amitriptyline Phase 2
- Apremilast Phase 2
- Axitinib Phase 1
- Benzoyl peroxide Phase 1
- BFH-772 Phase 2
- BMX-010 Phase 2
- Brimonidine Phase 3
- Calcium dobesilate Phase 1
- Clindamycin phosphate Phase 2
- Cromolyn sodium Phase 1
- Dapsone Phase 2
- Doxycycline hyclate Phase 3
- Erenumab Phase 2
- Gabapentin Phase 1
- Hydroxychloroquine Phase 1
- Imipramine Phase 2
- Imipramine pamoate Phase 2
- Incobotulinumtoxina Phase 2
- Isotretinoin Phase 3
Other linked drugs (8)
- Abobotulinumtoxina
- Botulinum toxin type A
- Salicylic acid
- Sumatriptan
- Sumatriptan succinate
- Tranexamic acid
- Trichloroacetic acid
- Zinc sulfate